852 related articles for article (PubMed ID: 28518283)
1. Branched-chain amino acids for people with hepatic encephalopathy.
Gluud LL; Dam G; Les I; Marchesini G; Borre M; Aagaard NK; Vilstrup H
Cochrane Database Syst Rev; 2017 May; 5(5):CD001939. PubMed ID: 28518283
[TBL] [Abstract][Full Text] [Related]
2. Branched-chain amino acids for people with hepatic encephalopathy.
Gluud LL; Dam G; Les I; Córdoba J; Marchesini G; Borre M; Aagaard NK; Vilstrup H
Cochrane Database Syst Rev; 2015 Feb; (2):CD001939. PubMed ID: 25715177
[TBL] [Abstract][Full Text] [Related]
3. Branched-chain amino acids for people with hepatic encephalopathy.
Gluud LL; Dam G; Les I; Córdoba J; Marchesini G; Borre M; Aagaard NK; Vilstrup H
Cochrane Database Syst Rev; 2015 Sep; (9):CD001939. PubMed ID: 26377410
[TBL] [Abstract][Full Text] [Related]
4. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Gluud LL; Vilstrup H; Morgan MY
Cochrane Database Syst Rev; 2016 Apr; 4():CD003044. PubMed ID: 27089005
[TBL] [Abstract][Full Text] [Related]
5. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Goh ET; Stokes CS; Sidhu SS; Vilstrup H; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2018 May; 5(5):CD012410. PubMed ID: 29762873
[TBL] [Abstract][Full Text] [Related]
6. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Gluud LL; Vilstrup H; Morgan MY
Cochrane Database Syst Rev; 2016 May; 2016(5):CD003044. PubMed ID: 27153247
[TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
Zacharias HD; Zacharias AP; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012334. PubMed ID: 31204790
[TBL] [Abstract][Full Text] [Related]
8. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.
Goh ET; Andersen ML; Morgan MY; Gluud LL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD002798. PubMed ID: 28745801
[TBL] [Abstract][Full Text] [Related]
9. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.
Goh ET; Andersen ML; Morgan MY; Gluud LL
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD002798. PubMed ID: 28796283
[TBL] [Abstract][Full Text] [Related]
10. Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Zacharias HD; Kamel F; Tan J; Kimer N; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD011585. PubMed ID: 37467180
[TBL] [Abstract][Full Text] [Related]
11. Branched-chain amino acids for hepatic encephalopathy.
Als-Nielsen B; Koretz RL; Kjaergard LL; Gluud C
Cochrane Database Syst Rev; 2003; (2):CD001939. PubMed ID: 12804416
[TBL] [Abstract][Full Text] [Related]
12. Probiotics for people with hepatic encephalopathy.
Dalal R; McGee RG; Riordan SM; Webster AC
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD008716. PubMed ID: 28230908
[TBL] [Abstract][Full Text] [Related]
13. Probiotics for patients with hepatic encephalopathy.
McGee RG; Bakens A; Wiley K; Riordan SM; Webster AC
Cochrane Database Syst Rev; 2011 Nov; (11):CD008716. PubMed ID: 22071855
[TBL] [Abstract][Full Text] [Related]
14. Acetyl-L-carnitine for patients with hepatic encephalopathy.
Martí-Carvajal AJ; Gluud C; Arevalo-Rodriguez I; Martí-Amarista CE
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD011451. PubMed ID: 30610762
[TBL] [Abstract][Full Text] [Related]
15. Dopamine agents for hepatic encephalopathy.
Junker AE; Als-Nielsen B; Gluud C; Gluud LL
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD003047. PubMed ID: 24515383
[TBL] [Abstract][Full Text] [Related]
16. Nutritional support for liver disease.
Koretz RL; Avenell A; Lipman TO
Cochrane Database Syst Rev; 2012 May; 2012(5):CD008344. PubMed ID: 22592729
[TBL] [Abstract][Full Text] [Related]
17. Ursodeoxycholic acid for primary biliary cirrhosis.
Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD000551. PubMed ID: 23235576
[TBL] [Abstract][Full Text] [Related]
18. Terlipressin versus other vasoactive drugs for hepatorenal syndrome.
Israelsen M; Krag A; Allegretti AS; Jovani M; Goldin AH; Winter RW; Gluud LL
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011532. PubMed ID: 28953318
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D supplementation for chronic liver diseases in adults.
Bjelakovic G; Nikolova D; Bjelakovic M; Gluud C
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011564. PubMed ID: 29099543
[TBL] [Abstract][Full Text] [Related]
20. Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome.
Allegretti AS; Israelsen M; Krag A; Jovani M; Goldin AH; Schulman AR; Winter RW; Gluud LL
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD005162. PubMed ID: 29943803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
